Vero Biotech

About:

Vero Biotech is a biopharmaceutical company that commercializes inhaled nitric oxide delivery systems for healthcare providers.

Website: https://www.vero-biotech.com

Twitter/X: verobiotech

Top Investors: Runway Growth Capital, MVM Life Science Partners, Petrichor Healthcare Capital Management

Description:

Vero Biotech is a biopharmaceutical company focused on the design, development, and commercialization of next-generation products to address the unmet medical needs of patients with a variety of pulmonary and cardiac diseases. They are currently developing inhaled nitric oxide (NO) products for use in both the hospital setting and for longer-term applications outside of the hospital setting. These products, which are based on our GeNOsylâ„¢ drug delivery technology, are comprised of a single-use drug cassette and either a portable console or wearable controller. Its technology is designed to deliver NO safely for a variety of therapeutic indications and to provide clinicians with a solution that is more user-friendly than currently available NO delivery systems.

Total Funding Amount:

$235M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Atlanta, Georgia, United States

Founded Date:

2006-01-01

Contact Email:

contactus(AT)genollc.com

Founders:

Number of Employees:

101-250

Last Funding Date:

2023-01-11

IPO Status:

Private

Industries:

© 2025 bioDAO.ai